Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2009

Commission File Number: 333-161602

CHINA CORD BLOOD CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this Form 6-K is filed, and the Company does not intend to update any of the forward-looking statements after the date this Report on Form 6-K is filed to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Form 6-K are subject to risks, uncertainties and assumptions about our businesses and business environments. These statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations; changing legislation or regulatory environments; requirements or changes affecting the businesses in which the Company is engaged; industry trends, including factors affecting supply and demand; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

Results of Operations and Financial Condition.

Following this cover page are the unaudited consolidated financial results for the three months and six months ended September 30, 2009 of China Cord Blood Corporation (the “Company”).

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of September 30 and March 31, 2009

	September 30,				March 31,
	2009				2009
	US$		RMB		RMB
(in thousands except redemption value and number of shares)

ASSETS
Current assets
Cash and cash equivalents		36,303		247,813		161,406
Accounts receivable, less allowance for doubtful accounts
(September 30, 2009: RMB6,764; March 31, 2009: RMB 6,170)		9,416		64,274		49,763
Inventories		763		5,211		6,501
Prepaid expenses and other receivables		1,171		7,990		7,978
Deferred tax assets		279		1,908		1,846
Total current assets		47,932		327,196		227,494
Property, plant and equipment, net		36,855		251,574		236,740
Non-current prepayments and deposits		3,013		20,569		27,184
Non-current accounts receivable, less allowance for doubtful accounts
(September 30, 2009: RMB3,793; March 31, 2009: RMB2,223)		20,823		142,144		91,761
Inventories		3,940		26,894		26,069
Intangible asset, net		3,923		26,783		27,268
Available-for-sale equity securities		6,130		41,843		26,242
Deferred reverse recapitalization costs		-		-		33,633
Deferred offering costs		129		878		-
Deferred tax assets		64		436		-
Total assets		122,809		838,317		696,391

LIABILITIES
Current liabilities
Bank loan		6,592		45,000		-
Accounts payable		979		6,681		5,128
Accrued expenses and other payables		2,982		20,353		19,269
Deferred revenue		4,238		28,927		18,351
Promissory note		514		3,510		-
Amounts due to related parties		516		3,523		-
Income tax payable		579		3,953		4,321
Total current liabilities		16,400		111,947		47,069
Deferred revenue		11,525		78,676		74,231
Other non-current liabilities		2,212		15,100		13,551
Deferred tax liabilities		476		3,249		4,017
Total liabilities		30,613		208,972		138,868

Commitments and contingencies
Redeemable ordinary shares of China Cord Blood Services Corporation
US$0.0001 par value, 14,614,140 shares issued and outstanding as of
March 31, 2009 (redemption value of US$51,088,745 as of March 31, 2009)		-		-		386,577

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of September 30 and March 31, 2009 – (continued)

	September 30,						March 31,
	2009						2009
	US$			RMB			RMB
(in thousands except redemption value and number of shares)

EQUITY
China Cord Blood Corporation shareholders’ equity
Ordinary shares US$0.0001 par value, 250,000,000 shares authorized,
43,237,100 shares and 62,792,642 shares issued and outstanding as
of March 31, 2009 and September 30, 2009, respectively		6			43			34
Additional paid-in capital		84,038			573,660			140,745
Accumulated other comprehensive loss		(517	)		(3,531	)		(19,319	)
Retained earnings		7,495			51,160			44,082
Total China Cord Blood Corporation shareholders’ equity		91,022			621,332			165,542
Noncontrolling interests		1,174			8,013			5,404
Total equity		92,196			629,345			170,946
Total liabilities, redeemable ordinary shares and equity		122,809			838,317			696,391

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Six Months Ended September 30, 2009 and 2008

	Three months ended September 30,									Six months ended September 30,
	2009						2008			2009						2008
	US$			RMB			RMB			US$			RMB			RMB
	(in thousands except per share)

Revenues		9,361			63,897			48,988			17,847			121,826			81,935
Direct costs		(2,583	)		(17,632	)		(11,667	)		(4,965	)		(33,888	)		(22,175	)
Gross profit		6,778			46,265			37,321			12,882			87,938			59,760
Operating expenses
Sales and marketing		(1,387	)		(9,470	)		(7,382	)		(2,419	)		(16,512	)		(15,047	)
General and administrative		(1,854	)		(12,651	)		(5,107	)		(3,549	)		(24,227	)		(10,978	)
Total operating expenses		(3,241	)		(22,121	)		(12,489	)		(5,968	)		(40,739	)		(26,025	)
Operating income		3,537			24,144			24,832			6,914			47,199			33,735
Other income/(expense), net
Interest income		252			1,723			938			404			2,755			1,911
Interest expense		(96	)		(657	)		-			(164	)		(1,117	)		-
Exchange gain/(loss)		66			451			(88	)		83			563			(81	)
Write-off of deferred
offering costs		-			-			(9,688	)		-			-			(9,688	)
Write-off of deferred reverse
capitalization costs		-			-			-			(3,159	)		(21,566	)		-
Impairment loss on available-
for-sale equity securities		-			-			(4,944	)		-			-			(27,598	)
Others		13			83			1,738			55			377			(1,146	)
Total other income/(expense), net		235			1,600			(12,044	)		(2,781	)		(18,988	)		(36,602	)
Income/(loss) before income tax		3,772			25,744			12,788			4,133			28,211			(2,867	)
Income tax expense		(933	)		(6,367	)		(5,840	)		(1,779	)		(12,141	)		(7,798	)
Net income/(loss)		2,839			19,377			6,948			2,354			16,070			(10,665	)
Income attributable to noncontrolling
interests		(204	)		(1,391	)		(1,169	)		(392	)		(2,676	)		(1,595	)
Income attributable to redeemable
noncontrolling interests		(51	)		(347	)		-			(51	)		(347	)		-
Net income/(loss) attributable to
China Cord Blood Corporation
shareholders		2,584			17,639			5,779			1,911			13,047			(12,260	)

Net income/(loss) per share:
Attributable to ordinary shares
-Basic		0.04			0.29			(0.01	)		0.02			0.12			(0.43	)
-Diluted		0.04			0.27			(0.01	)		0.02			0.11			(0.43	)

Attributable to redeemable ordinary shares
-Basic		N/A			N/A			0.42			0.13			0.92			0.44
-Diluted		N/A			N/A			0.42			0.13			0.92			0.44

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release dated December 11, 2009

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	China Cord Blood Corporation




	By:	/s/ Ting Zheng
	Name: Ting Zheng
	Title: Chairman and Chief Executive Officer

Dated: December 11, 2009